* Safe for short term use in patients with stage 1-2 CKD. Risk of causing AKI is same as in general population. No evidence that it will increase risk of progression. | * Safe for short term use in patients with stage 1-2 CKD. Risk of causing AKI is same as in general population. No evidence that it will increase risk of progression. |